Deal Structure Guide · Hospice & Palliative Care

How Hospice & Palliative Care Acquisitions Are Structured

From Medicare CHOW requirements to earnouts tied to census retention, understand the deal structures that define lower middle market hospice transactions — and how to negotiate terms that protect both sides.

Acquiring or selling a hospice agency involves considerably more structural complexity than a typical business sale. Every deal must account for Medicare certification continuity, CMS Change of Ownership (CHOW) requirements, billing compliance exposure, and the operational reality that revenue depends on a living census of patients receiving daily care. In the lower middle market — hospice agencies with $1M–$5M in revenue and $300K–$1.5M in EBITDA — transactions are typically structured as asset purchases with Medicare provider agreement novation, stock purchases that preserve existing certification, or equity rollover arrangements with PE-backed platforms. The choice of structure has direct implications for Medicare liability exposure, licensure continuity, staff retention, and the seller's post-close obligations. Buyers routinely use escrow holdbacks, earnouts tied to average daily census, and seller notes to manage compliance and operational transition risk. Sellers benefit most when they understand how each structure affects their liability, their team, and their ability to achieve a clean exit.

Find Hospice & Palliative Care Businesses For Sale

Asset Purchase with Medicare Provider Agreement Novation

The buyer acquires the hospice agency's operating assets — including patient census, contracts, equipment, and goodwill — but not its corporate entity. The Medicare provider agreement is novated to the new entity through a formal CMS CHOW process. This is the most common structure in hospice M&A and allows the buyer to assume operational control while limiting exposure to pre-closing liabilities. A seller note or earnout of 10–20% of the purchase price is frequently layered in to align incentives during the census transition period.

60–70% of hospice transactions in the lower middle market

Pros

  • Buyer limits exposure to pre-closing Medicare billing liabilities and legacy compliance issues tied to the seller's entity
  • Seller note or earnout tied to ADC retention post-close aligns both parties around a smooth patient census transition
  • Cleanest structure for SBA 7(a) financing, which is frequently used by owner-operator buyers acquiring Medicare-certified hospice agencies

Cons

  • CMS CHOW process can take 60–120 days, creating an extended period of operational uncertainty and delayed full control for the buyer
  • Medicare provider agreement novation does not eliminate all pre-closing billing exposure — buyers must conduct thorough Medicare cost report and RAC audit review
  • Asset allocation between goodwill, patient relationships, and clinical infrastructure must be carefully negotiated for tax efficiency on both sides

Best for: First-time hospice buyers using SBA financing, owner-operators acquiring a single agency for geographic entry, and deals where the seller's corporate entity has compliance history the buyer wants to isolate

Stock Purchase with Escrow Holdback for Compliance Contingencies

The buyer acquires the seller's corporate entity outright, including all assets, liabilities, contracts, and the existing Medicare provider agreement. This avoids a formal CHOW filing with CMS in many cases, preserving billing continuity and reducing transition disruption. However, the buyer inherits all historical liabilities including undisclosed Medicare overpayments, RAC audit exposure, and OIG risk. Escrow holdbacks of 10–15% of the purchase price held for 12–24 months are standard to cover post-close compliance discoveries.

25–35% of hospice transactions in the lower middle market

Pros

  • Existing Medicare provider agreement and NPI number are retained, eliminating CHOW delay and preserving uninterrupted billing and reimbursement flow
  • Preferred by PE-backed strategic acquirers executing rapid roll-up strategies where operational continuity and speed of integration matter most
  • Avoids asset purchase allocation complexities and can simplify employee transitions since existing employment relationships remain in the corporate entity

Cons

  • Buyer inherits all pre-closing liabilities including undisclosed Medicare overpayments, pending RAC audits, survey deficiencies, and employment claims
  • Requires extensive due diligence on Medicare cost reports, cap position, OIG exclusion screening, and historical billing practices to quantify inherited risk
  • Sellers may face post-close indemnification claims from escrow for compliance issues that surface during CMS audits occurring after transaction close

Best for: PE-backed platforms and strategic acquirers with experienced compliance teams, deals where CHOW delay would materially disrupt operations or referral relationships, and acquisitions of agencies with strong clean compliance records

Equity Rollover with PE-Backed Platform

The seller contributes their hospice agency into a PE-backed platform in exchange for a combination of cash at close and retained equity — typically 10–30% of the combined entity. The seller becomes a minority partner, often retaining an operational leadership role, and participates in the platform's future growth and eventual second exit. This structure is increasingly common as hospice roll-up platforms seek to acquire founder-operators who have built strong referral networks and want continued upside rather than a full exit.

10–15% of hospice transactions in the lower middle market

Pros

  • Seller retains meaningful equity upside in the platform's growth, providing a potential second exit at a higher multiple as the platform scales
  • Operational founders with strong referral relationships and clinical credibility remain engaged, reducing census disruption and referral source attrition post-close
  • Buyer acquires aligned partnership with a founder who has deep community trust, clinical staff loyalty, and established physician relationships that are difficult to replicate

Cons

  • Seller's liquidity is partially deferred and tied to platform performance, PE fund timelines, and eventual exit conditions outside their direct control
  • Complex securities documentation, rollover equity valuation, and governance rights negotiation require experienced healthcare M&A legal counsel on both sides
  • Sellers who want a clean retirement exit and full liquidity at close are poorly served by this structure — it requires continued engagement and operational involvement

Best for: Founder-operators aged 50–65 who want partial liquidity now, continued operational involvement, and a second bite at the apple through platform growth; ideal when the agency has a strong ADC trajectory and the seller's relationships are central to referral network retention

Sample Deal Structures

Retiring RN founder selling a Medicare-certified hospice with 65 ADC to an SBA-financed owner-operator buyer

$2,400,000

SBA 7(a) loan: $1,680,000 (70%); Seller note: $480,000 (20%); Buyer equity injection: $240,000 (10%)

Asset purchase structure with Medicare provider agreement novation. Seller note at 6.5% interest over 5 years, subordinated to SBA lender with 12-month standby period. Earnout component of $120,000 embedded within seller note, tied to ADC remaining at or above 60 patients at the 12-month post-close mark. Seller remains as a part-time clinical consultant for 6 months at $5,000 per month to support referral source transitions. Escrow holdback of $150,000 held for 18 months to cover Medicare cost report reconciliation and any RAC audit findings. Asset allocation: $900,000 to goodwill, $600,000 to patient relationships and referral network, $500,000 to Medicare certification and licensure value, $400,000 to equipment and EMR systems.

PE-backed hospice platform acquiring a regional agency with 110 ADC and two licensed locations for geographic roll-up expansion

$5,800,000

Cash at close: $4,060,000 (70%); Rollover equity in platform: $1,160,000 (20%); Escrow holdback: $580,000 (10%)

Stock purchase structure retaining existing Medicare provider agreements for both licensed locations. Seller receives cash at close plus 8% equity stake in the PE-backed platform, subject to a 3-year lockup and drag-along provisions on platform exit. Escrow holdback of $580,000 held for 24 months covering Medicare cap exposure, outstanding cost report settlements, and any OIG or CMS enforcement actions arising from pre-close billing periods. Seller transitions to Regional Director of Operations role at $140,000 annual compensation for a minimum 2-year term. Valuation based on 5.8x trailing 12-month EBITDA of $1,000,000, with a ratchet provision allowing purchase price adjustment if ADC falls below 95 patients in the first 6 months post-close.

Physician-founded palliative care practice with $1.2M revenue seeking clean exit to a regional home health and hospice consolidator

$1,500,000

Cash at close: $1,200,000 (80%); Seller note: $225,000 (15%); Earnout: $75,000 (5%)

Asset purchase with full CHOW filing to CMS. Seller note at 7% interest over 3 years, with full acceleration clause triggered by any CMS-initiated recoupment demand exceeding $50,000 during the seller note term. Earnout of $75,000 payable at 18 months post-close contingent on ADC exceeding 35 patients and no active OIG investigations. Seller provides 90-day transition support at no additional cost, including introductions to all hospital discharge planners, SNF social workers, and referring physicians. Buyer retains existing Director of Nursing at a 10% compensation increase as a retention incentive funded by the seller from proceeds at close. No representations and warranties insurance obtained due to deal size; indemnification caps set at 15% of purchase price for general reps and 100% for Medicare and tax representations.

Negotiation Tips for Hospice & Palliative Care Deals

  • 1Tie any earnout or seller note contingency directly to average daily census metrics rather than revenue, since ADC is the most reliable leading indicator of hospice operational health and is harder for either party to manipulate post-close
  • 2Require a Medicare cap analysis conducted by a healthcare reimbursement consultant as a condition of LOI — agencies approaching 90% or more of their annual cap limit pose material revenue risk that must be priced into the deal structure or addressed through escrow
  • 3In asset purchase transactions, negotiate a detailed CHOW timeline with CMS filing deadlines, milestone payments, and operational protocols explicitly defined so both parties understand what happens if CHOW approval is delayed beyond 90 days
  • 4Sellers should push for broad indemnification carve-outs that exclude liability for billing practices performed in compliance with the clinical documentation standards in place at time of service — blanket Medicare billing indemnification obligations are often overbroad and unreasonably expose sellers post-close
  • 5Buyers acquiring agencies with strong founder-operator referral relationships should negotiate a structured transition support agreement of at least 90–180 days with specific deliverables — introductions to all top referral sources, staff meetings, and family communication — not just a generic consulting clause
  • 6When structuring escrow holdbacks, define triggering events with specificity: distinguish between CMS administrative adjustments to cost reports versus active fraud investigations, and set a clear materiality threshold below which minor billing adjustments do not trigger holdback claims, protecting sellers from frivolous post-close disputes

Find Hospice & Palliative Care Businesses For Sale

Pre-screened targets ready for your deal structure — free to join.

Get Deal Flow

Frequently Asked Questions

Why do most hospice acquisitions use an asset purchase rather than a stock purchase?

Asset purchases allow buyers to limit their exposure to pre-closing Medicare liabilities — including undisclosed overpayments, RAC audit findings, and billing compliance issues — that would automatically transfer in a stock purchase. Since hospice agencies operate under heavy CMS oversight with complex billing histories spanning multiple cost report years, buyers prefer the cleaner liability profile of an asset purchase even though it requires a formal Medicare CHOW filing. Stock purchases are more common when speed of transaction is critical, when the seller's compliance record is clean and well-documented, or when a PE-backed platform has the internal compliance infrastructure to manage inherited risk.

What is a Medicare Change of Ownership (CHOW) and how does it affect a hospice acquisition timeline?

A CHOW is the formal CMS process by which a hospice agency's Medicare provider agreement is transferred to a new owner following an asset purchase. The buyer must submit a CHOW application to the MAC (Medicare Administrative Contractor) and receive CMS approval before billing under the new entity. This process typically takes 60–120 days and can extend deal timelines significantly. During this period, the seller often continues billing under their provider agreement under an interim management or administrative services agreement with the buyer. Buyers should model CHOW delay into their integration timeline and ensure the purchase agreement addresses billing rights, cash flow management, and operational authority during the CHOW transition period.

How are hospice agencies valued in lower middle market transactions?

Hospice agencies in the $1M–$5M revenue range are typically valued at 4x–7x trailing 12-month EBITDA, with the multiple driven by factors including average daily census size and trajectory, Medicare compliance history, referral source diversification, geographic market characteristics, and key staff retention. Agencies with ADC above 80 patients, clean survey records, and a tenured clinical leadership team command multiples at the higher end of the range. Agencies with compliance concerns, high staff turnover, or heavy referral source concentration trade at 4x–5x or face structural deal protections that effectively reduce net proceeds to the seller.

What is a Medicare annual cap and why does it matter in a hospice acquisition?

The Medicare hospice benefit includes an annual aggregate cap that limits total Medicare payments to a hospice agency based on the number of beneficiaries it serves during the cap year. Agencies that bill at or near this cap limit face recoupment of overpayments by CMS, which can be material — sometimes hundreds of thousands of dollars. In an acquisition, buyers must analyze the seller's current cap position and project forward exposure for the next 12–24 months. Cap exposure that is not disclosed or properly priced into the deal structure can significantly erode post-close returns, and sellers who are approaching the cap limit may face valuation reductions or deal-specific escrow requirements to cover potential recoupment obligations.

Can an SBA 7(a) loan be used to finance a hospice agency acquisition?

Yes, SBA 7(a) loans are eligible for hospice agency acquisitions and are a common financing tool for owner-operator buyers in the lower middle market. The SBA loan can cover up to 90% of the acquisition price, with the borrower providing a 10% equity injection. Lenders will underwrite the loan based on the agency's historical EBITDA, Medicare reimbursement stability, and the buyer's healthcare management experience. Key SBA eligibility considerations include the hospice agency's Medicare certification status, licensure in good standing, and at least two years of operating history. Sellers who carry a subordinated seller note — typically required to stand by for 12–24 months per SBA rules — can help bridge any valuation gaps between buyer and seller expectations.

What post-close protections should a buyer include in a hospice acquisition agreement?

Buyers should negotiate several layers of post-close protection specific to hospice transactions: an escrow holdback of 10–15% of purchase price held for 18–24 months to cover Medicare cost report settlements, RAC audit findings, and OIG matters; specific indemnification representations covering Medicare billing compliance, employee licensure, and referral source compliance with anti-kickback safe harbors; an ADC-based earnout or seller note contingency that ties a portion of seller proceeds to census retention; and a transition services agreement requiring the seller to actively support referral source introductions and staff retention for a defined post-close period. Representations and warranties insurance is available but often cost-prohibitive for sub-$3M deals, making strong contractual indemnification with clear caps and survival periods the primary protection mechanism.

More Hospice & Palliative Care Guides

More Deal Structure Guides

Start Finding Hospice & Palliative Care Deals Today — Free to Join

Find the right target, structure the deal, and close with confidence.

Create your free account

No credit card required